The critical path institute: Transforming competitors into collaborators

Nature Reviews Drug Discovery

Volumn 13, Issue 11, 2014, Pages 785-786

  Brumfield, Martha ^a  

^a CRITICAL PATH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CONSENSUS; DRUG RESEARCH; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE ORGANIZATION; INFORMATION DISSEMINATION; MEDICAL INFORMATION; MEDICAL RESEARCH; MENTAL DISEASE; NEUROLOGIC DISEASE; NOTE; PATENT; PATIENT CARE; POLICY; PROGRAM DEVELOPMENT; PUBLIC-PRIVATE PARTNERSHIP; RISK REDUCTION; STANDARDIZATION; UNITED STATES; CLINICAL PATHWAY; COOPERATION; DRUG APPROVAL; DRUG DEVELOPMENT; HUMAN; ORGANIZATION; PROCEDURES;

ACADEMIES AND INSTITUTES; COOPERATIVE BEHAVIOR; CRITICAL PATHWAYS; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84908476138     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4436     Document Type: Note

References (5)

1. Woodcock, J. & Woosley, R. The FDA Critical Path Initiative and its influence on new drug development. Annu. Rev. Med. 59,1-12 (2008).
2. Rogers, J. A. et al. Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a beta regression meta-analysis. J. Pharmacokinet. Pharmacodyn. 39, 479-498 (2012).
3. Yu, P. et al. Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. Neurobiol. Aging 35, 808-818 (2014).
4. Rudick, R. A. et al. Multiple Sclerosis Outcome Assessments Consortium: genesis and initial project plan. Mult. Scler. 20, 12-17 (2014).
5. Walker, E. G. et al. Evolving global regulatory science through the voluntary submission of data: a 2013 assessment. Ther. Innovation Regul. Sci. 48, 236-245 (2014).